UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

The lancet oncology, 2016-12, Vol.17 (12), p.1683-1696

2016

Volltextzugriff (PDF)

Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3303-3306

Langer, Corey J

2013

Volltextzugriff (PDF)

Exploring biomarkers in head and neck cancer

Cancer, 2012-08, Vol.118 (16), p.3882-3892

Langer, Corey J.

2012

Volltextzugriff (PDF)

Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors

American journal of clinical oncology, 2015-08, Vol.38 (4), p.422-430

Langer, Corey J

2015

Volltextzugriff (PDF)

Systemic therapy for elderly patients with non–small cell lung cancer: Where do we stand in 2019?

Cancer, 2020-03, Vol.126 (5), p.931-934

2020

Volltextzugriff (PDF)

A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma

PloS one, 2022-09, Vol.17 (9), p.e0275187-e0275187

2022

Volltextzugriff (PDF)

The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-12, Vol.28 (36), p.5311-5320

2010

Volltextzugriff (PDF)

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer: A Phase 2 Trial

JAMA oncology, 2019-09, Vol.5 (9), p.1283

2019

Volltextzugriff (PDF)

Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

JNCI : Journal of the National Cancer Institute, 2011-10, Vol.103 (19), p.1452-1460

2011

Volltextzugriff (PDF)

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.404-415

2020

Volltextzugriff (PDF)

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2490-2498

2017

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Cancer, 2020-11, Vol.126 (22), p.4867-4877

2020

Volltextzugriff (PDF)

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2017-04, Vol.106, p.1-7

2017

Volltextzugriff (PDF)

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1883-1892

2021

Volltextzugriff (PDF)

Scan-associated distress in lung cancer: Quantifying the impact of “scanxiety”

Lung cancer (Amsterdam, Netherlands), 2016-10, Vol.100, p.110-113

2016

Volltextzugriff (PDF)

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.162-168

2021

Volltextzugriff (PDF)

Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer

Clinical lung cancer, 2021-01, Vol.22 (1), p.49-57

2021

Volltextzugriff (PDF)

Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy

Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.1-8

2020

Volltextzugriff (PDF)

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

Lung cancer (Amsterdam, Netherlands), 2018-11, Vol.125, p.273-281

2018

Volltextzugriff (PDF)

Current Management of Brain Metastases, With a Focus on Systemic Options

Journal of clinical oncology, 2005-09, Vol.23 (25), p.6207-6219

2005

Volltextzugriff (PDF)

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2530-2535

2009

Volltextzugriff (PDF)

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2019-01, Vol.14 (1), p.124-129

2019

Volltextzugriff (PDF)

Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5255-5261

2009

Volltextzugriff (PDF)

National Cancer Database report on cancer of the head and neck: 10-Year update

Head & neck, 2009-06, Vol.31 (6), p.748-758

2009

Volltextzugriff (PDF)

1 – 25 von 618

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(575)
Mit Volltextzugriff
(556)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(311)
Life Sciences & Biomedicine
(304)
Humans
(292)
Oncology
(271)
Female
(172)
Male
(169)
Aged
(154)
Middle Aged
(153)
Lung Neoplasms - Drug Therapy
(139)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(125)
Adult
(103)
Lung Neoplasms - Pathology
(102)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(100)
Biological And Medical Sciences
(96)
Medical Sciences
(96)
Carcinoma, Non-Small-Cell Lung - Pathology
(81)
Treatment Outcome
(78)
Chemotherapy
(77)
Hematology, Oncology And Palliative Medicine
(69)
Aged, 80 And Over
(67)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?

Exploring biomarkers in head and neck cancer

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors

Systemic therapy for elderly patients with non–small cell lung cancer: Where do we stand in 2019?

A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma

The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer: A Phase 2 Trial

Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407

Scan-associated distress in lung cancer: Quantifying the impact of “scanxiety”

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer

Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

Current Management of Brain Metastases, With a Focus on Systemic Options

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases

National Cancer Database report on cancer of the head and neck: 10-Year update

Suchergebnisse filtern